Terumo Neuro to acquire Arsenal Medical for liquid embolic technology

Terumo Neuro signed an agreement to acquire Arsenal Medical, a clinical-stage biomaterials company developing NeoCast, an investigational liquid embolic technology for treating chronic subdural hematoma. The acquisition expands Terumo Neuro's neurovascular portfolio.

“NeoCast represents a compelling opportunity to advance what could be a game-changing innovation in the treatment of chronic subdural hematoma.”terumoneuro.com

• 1 source
• terumoneuro.comTerumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH) | Terumo NeuroSep 29, 2026

Summarized from public sources; check the original articles before acting on it.